Changing the Treatment Landscape: Embracing Long-Acting Injectable Antipsychotics

Activity Details
  • Credit Amounts:
  • Cost: Free
  • Release: Jun 17, 2019
  • Expires: Jun 17, 2020
  • Average User Rating:
    ( Ratings)

To complete this activity please click the link below

Click Here

 

Faculty

Leslie L.  Citrome Leslie L. Citrome, MD, MPH
New York Medical College
Valhalla, New York

Megan  Ehret Megan Ehret, PharmD, MS, BCPP
Associate Professor of Pharmacy Practice and Science
University of Maryland
Baltimore, Maryland

Deanna Kelly Deanna Kelly, PharmD, BCPP
Professor of Psychiatry
University of Maryland Baltimore School of Medicine
Baltimore, Maryland

Target Audience

This activity is designed to meet the educational needs of psychiatric and neurologic pharmacists.

Objectives

At the conclusion of this application-based activity, participants will be able to:
1. Review the evidence base of long-acting injectable antipsychotics (LAI) compared to oral antipsychotics with regards to adherence, hospitalization, relapse, and mortality.
2. Identify the role of LAIs in the treatment continuum and discuss their use earlier in the schizophrenia disease course.
3. Compare LAIs with regard to pharmacokinetic profiles, loading dose strategies, and chronic dosing.
4. Incorporate LAIs into treatment regimens using case-based examples